-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $58

Benzinga·11/20/2026 11:26:01
Diffusion vocale
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $64 to $58.